Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem® is a selective 11β-HSD1 inhibitor that is able to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in Alzheimer's disease (AD). The ongoing Phase II XanADu trial is fully enrolled with mild AD patients, who receive Xanamem in conjunction with
18 Mar 2019
Actinogen Medical - Differentiated treatment for Alzheimer’s disease
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Actinogen Medical - Differentiated treatment for Alzheimer’s disease
Actinogen Medical Limited (ACW:ASX) | 0 0 -9.4% | Mkt Cap: 35.9m
- Published:
18 Mar 2019 -
Author:
Dr Jonas Peciulis -
Pages:
20
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem® is a selective 11β-HSD1 inhibitor that is able to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in Alzheimer's disease (AD). The ongoing Phase II XanADu trial is fully enrolled with mild AD patients, who receive Xanamem in conjunction with